KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

Koga, Takamasa; Suda, Kenichi; Fujino, Toshio; Ohara, Shuta; Hamada, Akira; Nishino, Masaya; Chiba, Masato; Shimoji, Masaki; Takemoto, Toshiki; Arita, Takeo; Gmachl, Michael; Hofmann, Marco H.; Soh, Junichi; Mitsudomi, Tetsuya

doi:10.1016/j.jtho.2021.04.015

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

INTRODUCTION KRAS mutations have been recognized as undruggable for many years. Recently, novel KRAS G12C inhibitors such as sotorasib and adagrasib are being developed in clinical trials and have shown promising results in metastatic non-small cell lung cancer. However, it is strongly anticipate…